Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
5,309,425
-
Share change
-
-162,340
-
Total reported value
-
$7,858,363
-
Put/Call ratio
-
158%
-
Price per share
-
$1.48
-
Number of holders
-
55
-
Value change
-
-$215,046
-
Number of buys
-
13
-
Number of sells
-
22
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q4 2023
As of 31 Dec 2023,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,309,425 shares.
The largest 10 holders included
VANGUARD GROUP INC, Laurion Capital Management LP, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, MAI Capital Management, STATE STREET CORP, BLAIR WILLIAM & CO/IL, RENAISSANCE TECHNOLOGIES LLC, NORTHERN TRUST CORP, and ELKHORN PARTNERS LIMITED PARTNERSHIP.
This page lists
55
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.